<DOC>
	<DOCNO>NCT00428194</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Erlotinib cisplatin may make tumor cell sensitive radiation therapy . Giving erlotinib together cisplatin radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose erlotinib give together cisplatin radiation therapy treat patient stage IB , stage II , stage III , stage IVA cervical cancer .</brief_summary>
	<brief_title>Erlotinib , Cisplatin , Radiation Therapy Treating Patients With Stage IB-Stage IVA Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose erlotinib hydrochloride administer cisplatin pelvic radiotherapy patient stage IB-IVA squamous cell carcinoma cervix . Secondary - Determine toxicity profile regimen . OUTLINE : This multicenter , open-label , dose-escalation study erlotinib hydrochloride . Patients receive oral erlotinib hydrochloride daily day 1-35 cisplatin IV day 1 , 8 , 15 , 22 , 29 . Patients also undergo radiotherapy daily , 5 day week , approximately 5 week concurrently chemotherapy . Cohorts 3-6 patient receive escalate dos erlotinib hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose proceed 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow 6 week .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Diagnosis squamous cell carcinoma cervix Stage IBIVA disease Scheduled undergo standard radiotherapy receive weekly cisplatin ECOG performance status 02 Not pregnant Negative pregnancy test Fertile patient must use effective contraception â‰¥ 1 week completion study treatment Must able take oral medication Malabsorption syndrome Serious underlie medical condition would impair ability patient receive treatment Known hypersensitivity erlotinib hydrochloride Psychological , familial , sociological , geographical condition would preclude study compliance Less 21 day since prior nonapproved investigational drug Prior chemotherapy Prior radiotherapy Prior antiepidermal growth factor receptor treatment Prior gastrointestinal surgery limit absorption ( i.e. , require total parenteral nutrition ) Concurrent use follow agent therapy : Other antineoplastic antitumor agent Other chemotherapy Other investigational agent Radiotherapy Immunotherapy Anticancer hormonal therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
</DOC>